European Institute of womens health, Eurohealth health logo

eu: Eugenmed – Agenda for meeting 30th June 2015

EUGenMed Final conference “Presentation of the Roadmap” Tuesday, 30th June 2015, 8.15-16.30 at: The Permanent Representation of the  Federal Republic of Germany to the European Union, Rue Jacques de Lalaing 8-14,  1040 Brussels, Belgium. Through the establishment of a European Gender Health Network and several thematic  workshops,the European Gender Medicine Project (EUGenMed) developeda roadmap for the implementation of sex and gender in biomedicine and health research. We produced diverse instruments (position papers, policy briefs, review papers, implementation, recommendations, slides etc.) to aid the incorporation of sex and gender within the areas of medical research, health care and policy. Now, at our final conference, we will present these products and collectively define the road for future implementation. Programme: 8.15-9.45 Registration and coffee, informal discussions with project leaders 9.45-10.00 Welcome by the official host The Permanent Representation of the  Federal Republic of Germany to the European Union. 10.00-10.15 Welcome and representation of EUGenMed Project Partners Charité: Vera Regitz-Zagrosek, UM: Ineke Klinge, EIWH: Peggy Maguire, 10.15-10.30 Overview on the EUGenMed Project goals – The roadmap  Vera Regitz-Zagrosek 10.30-11.45  Results from WS clinical medicine and pharmacology (1.1) and basic research (1.3) Chairs: Vera Regitz-Zagrosek/Angela Maas Sex and gender issues in clinical cardiology Angela Maas, The Netherlands Drug therapy Karin Schenck-Gustafsson, Sweden Basic research Vera Regitz-Zagrosek, Germany  Discussion with all stakeholders 11.45-12.45 Results from WS on public health and prevention (1.2) Chairs: Ineke Klinge Facts in public health Lucie Dalibert, The Netherlands Implementation into public health practice and policy Sabine Oertelt-Prigione, Germany Discussion with stakeholders…

Read More

First National Sepsis Summit

First National Sepsis Summit Minister for Health Leo Varadkar,Thurs 2nd July 2015, addressed 180 delegates at first National Sepsis Summit in Dublin Castle. Sepsis is the 10th leading cause of death worldwide, more than bowel cancer, breast cancer, road traffic accidents and HIV/AIDS combined. In November Minister Varadkar endorsed a National Clinical Effectiveness Guideline to…

Read More

.scot: Health boards to reduce cancer waiting times

Health boards to reduce cancer waiting times Health boards share over £4 million to reduce cancer waiting times after performance target drop and will help improve on diagnostic wait across country and provide local support. In the first quarter of 2015, 91.8 per cent of patients urgently referred with suspicion of cancer began treatment within…

Read More

European Gender Medicine Project Final Conference

PRESS RELEASE European Gender Medicine Project hosts final conference in Brussels 30 June 2015, In a one day final conference hosted by the Permanent Representation of the Federal Republic of Germany to the European Union, the European Gender Medicine Project (EUGenMed) partners met with over eighty experts and stakeholders to discuss the future of Gender…

Read More

Recognise and resist sexual aggression

An intensive program for female college students on recognising and resisting sexual aggression reduced the chances of being raped over a year period by nearly half, according to new research. A study in the New England Journal of Medicine, compared effects of attending a four-session course in resisting sexual assault to a more typical university…

Read More

uk: Quality standards supporting care for conditions

Quality standards supporting care for conditions. Prostate cancer Prostate cancer is the most common cancer in men, with 35,567 diagnosed in England in 2011. It is more common in men aged over 65 and as the population ages, more cases are expected to occur. NICE published a quality standard to help the NHS provide high…

Read More

uk: draft guidance on drug to treat advanced prostate cancer

UK: NICE published draft guidance in which enzalutamide is not recommended as a drug to treat advanced prostate cancer.  It says enzalutamide. also called Xtandi, manufactured by Astellas Pharma) is not a cost effective, pre chemotherapy treatment with too many uncertainties associated with evidence provided by manufacturer.  …more

Read More

EGA conference – session 4, Health Equality, sustainable access to medicines

EGA conference: session 4, Health Equality, sustainable access to medicines Presentation by Peggy Maguire in her role as President, EPHA. Presentation outline:Background info re: EPHA & health inequalities Challenges and opportunities for narrowing health inequalities in Europe Changing healthcare environments Economic crisis & austerity Health literacy & patient empowerment Sex and gender in medications Investing…

Read More